What is it about?
The prevalence of obesity is increasing globally, and there is a need to monitor the effects of drug dosage from a pre- to post-gastric bypass scenario. The principal aim was to evaluate whether gastric bypass surgery modifies the bioavailability and pharmacokinetic (PK) parameters of omeprazole.
Featured Image
Photo by Simone van der Koelen on Unsplash
Why is it important?
Clinical bioavailability trial that evaluates whether Roux-en-Y gastric bypass (RYGB) modifies the pharmacokinetics of Omeprazole. Our study analyzes the absorption changes (pre- post surgery) in this special population, as well as compares pharmacokinetics after surgery vs matched controls. This knowledge is relevant given the highly prevalent use of omeprazole in this population.
Perspectives
Contribute to physicians’ ability on smart prescription, helping to predict the course and effects of commonly used drugs as omeprazole, in special populations as patients after RYGB are, upon clinical pharmacokinetics knowledge.
Rivas Paterna
Unidad de Investigación Clínica y Ensayos Clínicos, Hospital Clínico San Carlos. Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain
Contribute to physicians’ ability on smart prescription, helping to predict the course and effects of commonly used drugs as omeprazole, in special populations as patients after RYGB are, upon clinical pharmacokinetics knowledge.
MD, PhD ANTONIO PORTOLES
Universidad Complutense de Madrid
Read the Original
This page is a summary of: EFFECT OF OBESITY AND ROUX-EN-Y GASTRIC SURGERY ON OMEPRAZOLE PHARMACOKINETICS, Obesity Facts, January 2022, Karger Publishers,
DOI: 10.1159/000521570.
You can read the full text:
Contributors
The following have contributed to this page
